FindTrial
Sign In

A study to compare effect of three common locally applied medicines in alopecia areata (a disease causing patchy hair loss) of scalp.

A Randomized pilot study comparing efficacy of topical 0.03% Bimatoprost, 0.1% Mometasone furoate and 0.1 % Tacrolimus ointment in the treatment of localized Alopecia areata of scalp

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/02/017483
Enrollment
120
Registered
2019-02-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L638- Other alopecia areata

Interventions

Intervention1: Bimatoprost 0.03 %: 0.03% Bimatoprost twice daily for 24 weeks Control Intervention1: Mometasone 0.1%: Mometasone 0.1% once daily for 24 weeks Control Intervention2: Tacrolimus 0.1%: 0

Sponsors

Amit Bahuguna
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Alopecia Areata (AA) patients aged 12â??45 years 2. AA of scalp with a Severity of Alopecia Tool (SALT) score of S1 3. Patients having 03 or less patches 4. Consent to be part of the study, photograph & regular follow up

Exclusion criteria

Exclusion criteria: 1. History of side effects to Bimatoprost, Mometasone or Tacrolimus. 2. Patients treated earlier within 3 months of the study 3. Patients with any evidence of atrophy in the lesions 4. Patients with alopecia totalis, alopecia universalis or ophiasis pattern of AA 5. Patients with history of spontaneous hair re-growth 6. Pregnant or lactating patients

Design outcomes

Primary

MeasureTime frame
i. Hair regrowth- 5 point semi-quantitative score, regrowth scale (RGS)and Global assessment of 100% Timepoint: 24 weeks—

Secondary

MeasureTime frame
AtrophyTimepoint: 24 Weeks;relapse Timepoint: 24 weeeks—

Countries

India

Contacts

Public ContactAmit Bahuguna

Army Medical Corps

afmcrocks@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026